Cancer Vaccines: From Research to Clinical Practice

With the first therapeutic cancer vaccine approved by the FDA in April 2010, and other vaccines currently in the pipeline, the interest in this developing area is set to increase exponentially.

Breaking new grounds,Cancer Vaccines provides a state of the art perspective on a projected, rapidly growing field, and describes the successful journey of the first licensed therapeutic vaccines for cancer, from design to approval.

Written and edited by key personnel in industry and academia working within cancer vaccines development, this book is the result of a global collaborative effort integrating industry, academia, non-for profit, with participation from members of regulatory agencies.

Key features:

• Highlights major vaccines and platform technologies in early or late development, nearing approval
• Introduces emerging technologies that could yield novel classes of drugs bridging active and passive immunotherapies
• Provides an update of pipeline and approved cancer vaccines
• Encompasses both scientific, translational as well as development aspects
• Includes an introductory chapter on the immune systems role in cancer and a closing chapter on the challenges involved in cancer vaccine development

An essential read for:

• Cancer immunologists in academia and industry
• Drug developers in the area of oncology biotherapies
• Clinical physicians involved in clinical trials of cancer biotherapies
• Regulatory agencies

1. 1. Introduction: Cancer vaccines: mechanism and a clinical overview
   Antoni Ribas and Adrian Bot
2. 2. Revisiting the paradigm on the putative need for antigen-specific responses in cancer
   Gail D. Sckisel, Julia K. Tietze, and William J. Murphy

   VACCINE PLATFORMS FOR GENITO-URINARY CANCERS, WITH POTENTIAL APPLICABILITY TO OTHER TUMORS

3. 3. Development of novel immune interventions for genito-urinary cancers
   Neeraj Agarwal and Nicholas J. Vogelzang
4. 4. Autologous cellular immunotherapy in late-stage prostate cancer: The development history of sipuleucel-T (PROVENGE®)
   David L. Urdal and Mark W. Frohlich
5. 5. Design, development and translation of poxvirus-based vaccines for cancer
   Benedetto Farsaci, Anna Kwilas, and James W. Hodge

   VACCINES FOR SOLID CANCERS AND HEMATOLOGICAL MALIGNANCIES

6. 6. Of mice and men (and dogs!): The first approved cancer therapy vaccine
   Philip J. Bergman and Jedd D. Wolchok
7. 7. Recombinant protein vaccination for antigen-specific cancer immunotherapy
   Pedro de Sousa Alves and Vincent Brichard
8. 8. Antigen-targeted, synthetic vaccines for metastatic cancer
   Zhiyong Qiu, David C. Diamond, Kent A. Smith, Dar Rosario, Sabrina Miles, Mihail Obrocea, Thomas M. Kundig and Adrian Bot
9. 9. Clinical perspectives in cancer vaccines for hematological diseases
   Maurizio Chiriva-Internati, Leonardo Mirandola, Marjorie Jenkins, Martin Cannon, Everardo Cobos, and W. Martin Kast
10. Epitope-based vaccines for cancer
    Vy Phan-Lai, Denise L. Cecil, Gregory E. Holt, Daniel R. Herendeen, Forrest Kievit, Miqin Zhang, and Mary L. Disis

    VACCINE DEVELOPMENT: TRIAL DESIGN AND IMMUNE ASSAYS

11. 11. Emerging clinical trial design concepts for therapeutic cancer vaccines
    Christina Musselli, Leah Isakov, and Kerry Wentworth
12. 12. T-cell immune monitoring assays to guide the development of new cancer vaccines
    Cedrik M. Britten, Sylvia Janetzki, Cecile Gouttefangeas, Marij J.P. Welters, Michael Kalos, Christian Ottensmeier, Axel Hoos, and Sjoerd H. van der Burg
13. 13. A biomarker-based, systems biology approach guiding the development of active immunotherapies and immune monitoring
    Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron, and Rafick-Pierre Sékaly

    EMERGING NEW VACCINE STRATEGIES, TARGETS, AND ADJUVANTS

14. 14. Targeting regulatory T cells and other strategies to enable cancer vaccines
    Christopher Paustian, Shawn M. Jensen, Sarah Church, Sachin Puri, Chris Twitty, Hong-Ming Hu, Brendan D. Curti, Walter J. Urba, Raj K. Puri and Bernard A. Fox
15. 15. Molecular targeting of cancer stem cells
    Zhenhua Li, Debraj Mukherjee, Jang-Won Lee, and John S. Yu
16. 16. RNA in cancer vaccine therapy
    Smita Nair, David Boczkowski, Scott Pruitt, and Johannes Urban
17. 17. Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines?
    Bo Jin and Anthony E.T. Yeo

    NEXT-GENERATION HYBRID ACTIVE/PASSIVE IMMUNOTHERAPIES

18. 18. Passive immunotherapy by T cell-engaging bispecific antibodies
    Patrick A. Baeuerle and Benno Rattel
19. 19. Antibodies to peptide-HLA complexes have potential application for cancer diagnosis and therapy
    Jon A. Weidanz and William H. Hildebrand